Ensign Peak Advisors Inc Invests $3.05 Million in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Ensign Peak Advisors Inc purchased a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 190,557 shares of the company’s stock, valued at approximately $3,047,000. Ensign Peak Advisors Inc owned about 0.36% of Tyra Biosciences as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TYRA. RA Capital Management L.P. increased its position in shares of Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after acquiring an additional 3,180,155 shares during the period. BVF Inc. IL increased its holdings in Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after purchasing an additional 1,921,599 shares during the period. Vanguard Group Inc. raised its position in Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after purchasing an additional 140,833 shares during the last quarter. Kynam Capital Management LP lifted its holdings in Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after buying an additional 175,000 shares during the period. Finally, American Century Companies Inc. grew its position in shares of Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after buying an additional 145,346 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Insider Buying and Selling at Tyra Biosciences

In other news, CEO Todd Harris sold 10,092 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.13, for a total value of $243,519.96. Following the sale, the chief executive officer now directly owns 1,479,528 shares of the company’s stock, valued at $35,701,010.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 16,390 shares of company stock worth $396,444. 15.40% of the stock is owned by insiders.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $23.40 on Friday. Tyra Biosciences, Inc. has a 1 year low of $10.38 and a 1 year high of $25.14. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -13.93 and a beta of 1.01. The company has a 50-day moving average of $21.55 and a 200 day moving average of $18.84.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TYRA. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Wedbush reaffirmed an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research note on Thursday, August 8th. Oppenheimer increased their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Finally, Piper Sandler started coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Tyra Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.